ARTICLE | Top Story
NICE backs Soliris without lifting veil
December 2, 2014 3:36 AM UTC
The U.K.'s NICE issued a final evaluation determination recommending Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) to treat atypical hemolytic uremic syndrome (aHUS) without receiving the specific answers it sought about the costs to develop the Orphan drug.
NICE estimated the humanized mAb targeting complement 5 (C5) will cost NHS up to L57.8 million ($90.5 million) in the first year, rising to L82 million ($128.4 million) in five years. ...